Skip to main content

Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.

Tohmola N, Itkonen O, Sane T, Markkanen H, Joenväärä S, Renkonen R, Hämäläinen E

Publication: Clin Chim Acta (2014) • Vol 428 • Page 38-43PMID: 24211728View on PubMed

Purpose

The purpose of this paper was to determine the effects of refrigerated and frozen storage, fasting, collection timing, tube type, patient age and gender on levels of 5-hydroxyindoleacetic acid (5-HIAA) in serum from healthy individuals. The authors also compared levels of serum 5-HIAA and urinary 5-HIAA and plasma chromogranin A(CgA) in healthy individuals and patients with neuroendocrine tumors.

Conclusion

Levels of serum 5-HIAA were stable for at least 7 days at 4 degrees C, 98 days at -20 degrees C (longest durations examined) and 5 freeze-thaw cycles. Further, comparable 5-HIAA levels were found in specimens stored for 10-12 years at -80 degrees C and those newly obtained and stored at -20 degrees C. Neither timing of collection nor patient fasting before collection affected serum 5-HIAA levels. Levels of 5-HIAA in serum were significantly higher when blood was collected into glass tubes than gel tubes. Patient age and gender had no effect on 5-HIAA levels. Levels of 5-HIAA in serum and urine and levels of CgA in plasma were higher in specimens from patients with neuroendocrine tumors than in healthy individuals, and levels in serum were correlated with those in urine and plasma. There were no significant differences in diagnostic specificity for neuroendocrine tumors between serum (97%), plasma (86%) and urine (100%) specimens.

Studies (1)

Purpose

The purpose of this study was to determine the effects of refrigerated and frozen storage, fasting, collection timing, tube type, patient age and gender on levels of 5-HIAA in serum from healthy individuals. The levels and diagnostic specificity of serum 5-HIAA and urinary 5-HIAA and plasma CgA in healthy individuals and patients with neuroendocrine tumors were also investigated. Serum from 9 healthy patients was used to determine the effects of delayed analysis and freeze-thaw cycling. Serum from 18 healthy volunteers was used to determine the effects of collection tube type. Serum from 24 healthy patients was collected before and after breakfast, and diurnal variation was investigated using thawed serum from 7 healthy individuals. Serum 5-HIAA levels were compared with urinary 5-HIAA levels by HPLC and plasma CgA levels by RIA in 112-129 patients with neuroendocrine tumors and 8 healthy individuals. Age and gender effects were investigated using 111 serum specimens from healthy individuals. Unless otherwise specified, all specimens were stored at -20 degrees C until analysis.

Summary of Findings

Levels of serum 5-HIAA were stable for at least 7 days at 4 degrees C, 98 days at -20 degrees C (longest durations examined) and 5 freeze-thaw cycles. Further, comparable 5-HIAA levels were found in specimens stored for 10-12 years at -80 degrees C and those newly obtained and stored at -20 degrees C. Serum 5-HIAA levels were not different between specimens taken after a 12 h fast and after breakfast, or between specimens collected at 8 AM, noon and 4 PM. Levels of 5-HIAA in serum were higher when blood was collected into glass tubes than gel tubes (p=0.0413), and while collection tube type had no other effects on levels of 5-HIAA, the authors recommend against the use of plasma. Patient age and gender had no effect on 5-HIAA levels. Levels of 5-HIAA in serum and urine and levels of CgA in plasma were higher in specimens from patients with neuroendocrine tumors than in healthy individuals (p<0.001), and levels in serum were correlated with those in urine and plasma. There were no significant difference in diagnostic specificity for neuroendocrine tumors between serum (97%), plasma (86%) and urine (100%) specimens.

  • Biospecimens

    FluidPlasma
    FluidUrine
    FluidSerum
    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    NeoplasticCarcinoma
  • Platforms

    Small moleculeHPLC
    Small moleculeLC-MS or LC-MS/MS
    ProteinRadioimmunoassay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionPatient age
    18-30 years
    31-50 years
    51-70 years
    >70 years
    PreaquisitionPatient gender
    Female
    Male
    Biospecimen AcquisitionBiospecimen location
    Plasma
    Serum
    Urine
    Biospecimen AcquisitionTime of biospecimen collection
    4 PM
    8 AM
    After 12 h fast
    After breakfast
    Noon
    Biospecimen AcquisitionType of collection container/solution
    Glass tube
    Lithium-heparin tubes
    Serum catalyzator tubes
    Serum gel tubes
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum
    StorageFreeze/thaw cycling
    1 cycle
    2 cycles
    3 cycles
    4 cycles
    5 cycles
    StorageStorage duration
    0 days
    1 day
    10-12 years
    14 days
    2 days
    21 days
    3 days
    35 days
    4 days
    5 days
    56 days
    6 days
    7 days
    98 days
    StorageStorage temperature
    -20 degrees C
    4 degrees C